Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Ideaya Biosciences, Inc. (IDYA) since 2019 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Ideaya Biosciences, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1676725.
Total stock buying since 2019: $22,722,685.
Total stock sales since 2019: $34,567,722.
Total stock option exercises since 2019: $5,195,646.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2025 | 0 | $0 | 0 | $0 | 38,424 | $750,036 |
| 2024 | 0 | $0 | 384,500 | $16,279,374 | 431,984 | $2,419,205 |
| 2023 | 0 | $0 | 130,470 | $4,192,321 | 143,571 | $934,680 |
| 2021 | 0 | $0 | 134,410 | $2,944,830 | 64,500 | $539,320 |
| 2020 | 120,527 | $1,722,685 | 815,252 | $11,151,197 | 78,537 | $351,177 |
| 2019 | 2,100,000 | $21,000,000 | 0 | $0 | 45,970 | $201,228 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2025-02 | 0 | $0 | 0 | $0 | 38,424 | $750,036 |
| 2024-06 | 0 | $0 | 0 | $0 | 53,484 | $544,199 |
| 2024-05 | 0 | $0 | 203,500 | $8,492,565 | 203,500 | $1,120,759 |
| 2024-02 | 0 | $0 | 102,000 | $4,615,841 | 100,000 | $430,998 |
| 2024-01 | 0 | $0 | 79,000 | $3,170,968 | 75,000 | $323,249 |
| 2023-12 | 0 | $0 | 87,000 | $3,046,000 | 95,000 | $526,749 |
| 2023-11 | 0 | $0 | 5,163 | $155,359 | 5,163 | $66,396 |
| 2023-09 | 0 | $0 | 6,837 | $205,244 | 4,837 | $62,203 |
| 2023-08 | 0 | $0 | 17,500 | $464,315 | 5,000 | $66,700 |
| 2023-07 | 0 | $0 | 9,485 | $218,173 | 9,485 | $94,233 |
| 2023-06 | 0 | $0 | 3,553 | $81,793 | 3,553 | $24,906 |
| 2023-05 | 0 | $0 | 932 | $21,437 | 932 | $6,533 |
| 2023-04 | 0 | $0 | 0 | $0 | 19,601 | $86,960 |
| 2021-10 | 0 | $0 | 1,500 | $39,351 | 1,500 | $16,620 |
| 2021-09 | 0 | $0 | 24,000 | $636,182 | 11,500 | $88,098 |
| 2021-08 | 0 | $0 | 11,500 | $267,237 | 1,500 | $6,464 |
| 2021-07 | 0 | $0 | 31,500 | $761,061 | 31,500 | $301,680 |
| 2021-06 | 0 | $0 | 5,000 | $112,413 | 5,000 | $34,599 |
| 2021-05 | 0 | $0 | 5,000 | $101,095 | 5,000 | $34,600 |
| 2021-02 | 0 | $0 | 53,409 | $981,110 | 7,000 | $48,559 |
| 2021-01 | 0 | $0 | 2,501 | $46,381 | 1,500 | $8,700 |
| 2020-12 | 0 | $0 | 1,979 | $29,884 | 15,750 | $67,882 |
| 2020-11 | 0 | $0 | 800,000 | $10,928,000 | 0 | $0 |
| 2020-06 | 120,527 | $1,722,685 | 13,273 | $193,313 | 10,223 | $55,195 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-02-18 | Hata Yujiro S (President and CEO) | Option Ex | 25,616 | 19.52 | 500,024 |
| 2024-06-27 | Throne Jason (Chief Legal Officer) | Option Ex | 53,484 | 10.18 | 544,199 |
| 2024-05-29 | White Michael Anthony (Chief Scientific Officer) | Sale | 28,500 | 36.50 | 1,040,278 |
| 2024-05-29 | White Michael Anthony (Chief Scientific Officer) | Option Ex | 28,500 | 12.86 | 366,510 |
| 2024-05-16 | Hata Yujiro S (President and CEO) | Sale | 34,433 | 42.05 | 1,447,907 |
| 2024-05-16 | Hata Yujiro S (President and CEO) | Option Ex | 34,433 | 4.31 | 148,406 |
| 2024-05-15 | Hata Yujiro S (President and CEO) | Sale | 83,856 | 43.39 | 3,638,511 |
| 2024-05-15 | Hata Yujiro S (President and CEO) | Option Ex | 83,856 | 4.31 | 361,419 |
| 2024-05-14 | Hata Yujiro S (President and CEO) | Sale | 56,711 | 41.72 | 2,365,869 |
| 2024-05-14 | Hata Yujiro S (President and CEO) | Option Ex | 56,711 | 4.31 | 244,424 |
| 2024-02-09 | Ruiz Briseno Andres (See Remarks) | Sale | 2,000 | 46.02 | 92,044 |
| 2024-02-09 | Hata Yujiro S (President and CEO) | Sale | 23,557 | 45.54 | 1,072,715 |
| 2024-02-09 | Hata Yujiro S (President and CEO) | Option Ex | 23,557 | 4.31 | 101,530 |
| 2024-02-08 | Hata Yujiro S (President and CEO) | Sale | 75,815 | 45.15 | 3,422,819 |
| 2024-02-08 | Hata Yujiro S (President and CEO) | Option Ex | 75,815 | 4.31 | 326,762 |
| 2024-02-01 | Hata Yujiro S (President and CEO) | Sale | 628 | 45.01 | 28,263 |
| 2024-02-01 | Hata Yujiro S (President and CEO) | Option Ex | 628 | 4.31 | 2,706 |
| 2024-01-22 | Ruiz Briseno Andres (See Remarks) | Sale | 2,000 | 42.02 | 84,050 |
| 2024-01-16 | Hata Yujiro S (President and CEO) | Sale | 62,739 | 40.17 | 2,519,974 |
| 2024-01-16 | Hata Yujiro S (President and CEO) | Option Ex | 62,739 | 4.31 | 270,405 |
| 2024-01-12 | Ruiz Briseno Andres (See Remarks) | Sale | 2,000 | 38.01 | 76,026 |
| 2024-01-12 | Hata Yujiro S (President and CEO) | Sale | 12,261 | 40.04 | 490,918 |
| 2024-01-12 | Hata Yujiro S (President and CEO) | Option Ex | 12,261 | 4.31 | 52,844 |
| 2023-12-18 | Throne Jason (Chief Legal Officer) | Option Ex | 10,000 | 7.01 | 70,100 |
| 2023-12-15 | Throne Jason (Chief Legal Officer) | Sale | 10,000 | 35.04 | 350,370 |
| 2023-12-15 | Throne Jason (Chief Legal Officer) | Option Ex | 10,000 | 13.34 | 133,400 |
| 2023-12-15 | Hata Yujiro S (President and CEO) | Sale | 75,000 | 35.03 | 2,627,624 |
| 2023-12-15 | Hata Yujiro S (President and CEO) | Option Ex | 75,000 | 4.31 | 323,249 |
| 2023-12-14 | Ruiz Briseno Andres (See Remarks) | Sale | 2,000 | 34.00 | 68,006 |
| 2023-11-03 | Throne Jason (Chief Legal Officer) | Sale | 5,163 | 30.09 | 155,359 |
| 2023-11-03 | Throne Jason (Chief Legal Officer) | Option Ex | 5,163 | 12.86 | 66,396 |
| 2023-09-12 | Throne Jason (Chief Legal Officer) | Sale | 1,000 | 30.00 | 30,005 |
| 2023-09-12 | Throne Jason (Chief Legal Officer) | Option Ex | 1,000 | 12.86 | 12,860 |
| 2023-09-05 | Throne Jason (Chief Legal Officer) | Sale | 1,737 | 30.03 | 52,160 |
| 2023-09-05 | Throne Jason (Chief Legal Officer) | Option Ex | 1,737 | 12.86 | 22,337 |
| 2023-09-01 | Ruiz Briseno Andres (See Remarks) | Sale | 2,000 | 30.01 | 60,016 |
| 2023-09-01 | Throne Jason (Chief Legal Officer) | Sale | 2,100 | 30.03 | 63,063 |
| 2023-09-01 | Throne Jason (Chief Legal Officer) | Option Ex | 2,100 | 12.86 | 27,006 |
| 2023-08-29 | Stone Paul A. (Chief Financial Officer) | Sale | 5,000 | 28.87 | 144,350 |
| 2023-08-21 | Stone Paul A. (Chief Financial Officer) | Sale | 978 | 26.40 | 25,819 |
| 2023-08-18 | Stone Paul A. (Chief Financial Officer) | Sale | 3,822 | 26.38 | 100,820 |
| 2023-08-16 | Stone Paul A. (Chief Financial Officer) | Sale | 200 | 26.43 | 5,285 |
| 2023-08-09 | Throne Jason (Chief Legal Officer) | Sale | 5,000 | 25.09 | 125,429 |
| 2023-08-09 | Throne Jason (Chief Legal Officer) | Option Ex | 5,000 | 13.34 | 66,700 |
| 2023-08-09 | Stone Paul A. (Chief Financial Officer) | Sale | 2,500 | 25.05 | 62,612 |
| 2023-07-10 | Throne Jason (Chief Legal Officer) | Sale | 9,485 | 23.00 | 218,173 |
| 2023-07-10 | Throne Jason (Chief Legal Officer) | Option Ex | 9,485 | 9.94 | 94,233 |
| 2023-06-01 | Throne Jason (Chief Legal Officer) | Sale | 3,553 | 23.02 | 81,793 |
| 2023-06-01 | Throne Jason (Chief Legal Officer) | Option Ex | 3,553 | 7.01 | 24,906 |
| 2023-05-31 | Throne Jason (Chief Legal Officer) | Sale | 432 | 23.00 | 9,937 |
| 2023-05-31 | Throne Jason (Chief Legal Officer) | Option Ex | 432 | 7.01 | 3,028 |
| 2023-05-22 | Throne Jason (Chief Legal Officer) | Sale | 500 | 23.00 | 11,500 |
| 2023-05-22 | Throne Jason (Chief Legal Officer) | Option Ex | 500 | 7.01 | 3,505 |
| 2023-04-13 | Stone Paul A. (Chief Financial Officer) | Option Ex | 8,000 | 4.62 | 36,960 |
| 2023-04-12 | Hata Yujiro S (President and CEO) | Option Ex | 11,601 | 4.31 | 50,000 |
| 2021-10-04 | Dillon Michael P. (SVP, Chief Scientific Officer) | Sale | 1,500 | 26.23 | 39,351 |
| 2021-10-04 | Dillon Michael P. (SVP, Chief Scientific Officer) | Option Ex | 1,500 | 11.08 | 16,620 |
| 2021-09-08 | Dillon Michael P. (SVP, Chief Scientific Officer) | Sale | 11,384 | 27.54 | 313,515 |
| 2021-09-08 | Dillon Michael P. (SVP, Chief Scientific Officer) | Option Ex | 11,384 | 7.70 | 87,599 |
| 2021-09-07 | Stone Paul A. (SVP, Chief Financial Officer) | Sale | 2,500 | 27.42 | 68,542 |
| 2021-09-07 | Dillon Michael P. (SVP, Chief Scientific Officer) | Sale | 116 | 27.46 | 3,185 |
| 2021-09-07 | Dillon Michael P. (SVP, Chief Scientific Officer) | Option Ex | 116 | 4.31 | 499 |
| 2021-09-02 | Dillon Michael P. (SVP, Chief Scientific Officer) | Sale | 10,000 | 25.09 | 250,940 |
| 2021-08-09 | Dillon Michael P. (SVP, Chief Scientific Officer) | Sale | 11,500 | 23.24 | 267,237 |
| 2021-08-09 | Dillon Michael P. (SVP, Chief Scientific Officer) | Option Ex | 1,500 | 4.31 | 6,464 |
| 2021-07-27 | Throne Jason (SVP, General Counsel) | Sale | 10,000 | 25.17 | 251,680 |
| 2021-07-27 | Throne Jason (SVP, General Counsel) | Option Ex | 10,000 | 13.34 | 133,400 |
| 2021-07-27 | Dillon Michael P. (SVP, Chief Scientific Officer) | Sale | 10,000 | 25.15 | 251,460 |
| 2021-07-27 | Dillon Michael P. (SVP, Chief Scientific Officer) | Option Ex | 10,000 | 5.62 | 56,150 |
| 2021-07-06 | Throne Jason (SVP, General Counsel) | Sale | 10,000 | 22.42 | 224,200 |
| 2021-07-06 | Throne Jason (SVP, General Counsel) | Option Ex | 10,000 | 10.18 | 101,750 |
| 2021-07-06 | Dillon Michael P. (SVP, Chief Scientific Officer) | Sale | 1,500 | 22.48 | 33,721 |
| 2021-07-06 | Dillon Michael P. (SVP, Chief Scientific Officer) | Option Ex | 1,500 | 6.92 | 10,380 |
| 2021-06-17 | Dillon Michael P. (SVP, Chief Scientific Officer) | Sale | 3,893 | 22.49 | 87,541 |
| 2021-06-17 | Dillon Michael P. (SVP, Chief Scientific Officer) | Option Ex | 3,893 | 6.92 | 26,939 |
| 2021-06-16 | Dillon Michael P. (SVP, Chief Scientific Officer) | Sale | 1,107 | 22.47 | 24,872 |
| 2021-06-16 | Dillon Michael P. (SVP, Chief Scientific Officer) | Option Ex | 1,107 | 6.92 | 7,660 |
| 2021-05-11 | Dillon Michael P. (SVP, Chief Scientific Officer) | Sale | 5,000 | 20.22 | 101,095 |
| 2021-05-11 | Dillon Michael P. (SVP, Chief Scientific Officer) | Option Ex | 5,000 | 6.92 | 34,600 |
| 2021-02-10 | Lackner Mark (SVP, Head of Biology) | Sale | 596 | 21.00 | 12,516 |
| 2021-02-10 | Lackner Mark (SVP, Head of Biology) | Option Ex | 596 | 6.98 | 4,160 |
| 2021-02-09 | Dillon Michael P. (SVP, Chief Scientific Officer) | Sale | 5,000 | 20.74 | 103,695 |
| 2021-02-09 | Dillon Michael P. (SVP, Chief Scientific Officer) | Option Ex | 5,000 | 6.92 | 34,600 |
| 2021-02-09 | Lackner Mark (SVP, Head of Biology) | Sale | 1,104 | 21.05 | 23,234 |
| 2021-02-09 | Lackner Mark (SVP, Head of Biology) | Option Ex | 1,104 | 6.98 | 7,705 |
| 2021-02-08 | Lackner Mark (SVP, Head of Biology) | Sale | 300 | 21.01 | 6,303 |
| 2021-02-08 | Lackner Mark (SVP, Head of Biology) | Option Ex | 300 | 6.98 | 2,094 |
| 2021-02-02 | Lampert Mark N | Sale | 46,409 | 18.00 | 835,362 |
| 2021-01-26 | Lackner Mark (SVP, Head of Biology) | Sale | 2,501 | 18.55 | 46,381 |
| 2021-01-26 | Lackner Mark (SVP, Head of Biology) | Option Ex | 1,500 | 5.80 | 8,700 |
| 2020-12-22 | Hata Yujiro S (President and CEO) | Option Ex | 8,000 | 4.31 | 34,480 |
| 2020-12-18 | Dillon Michael P. (SVP, Chief Scientific Officer) | Option Ex | 7,750 | 4.31 | 33,402 |
| 2020-12-04 | Throne Jason (SVP, General Counsel) | Sale | 1,979 | 15.10 | 29,884 |
| 2020-11-11 | Rocklage Scott M (10% Owner) | Sale | 800,000 | 13.66 | 10,928,000 |
| 2020-06-30 | Lampert Mark N | Buy | 2,531 | 13.32 | 33,702 |
| 2020-06-22 | Lampert Mark N | Buy | 19,732 | 13.94 | 274,965 |
| 2020-06-19 | Lampert Mark N | Buy | 98,264 | 14.39 | 1,414,018 |
| 2020-06-17 | Stone Paul A. (Chief Financial Officer) | Sale | 3,100 | 18.72 | 58,041 |
| 2020-06-17 | Stone Paul A. (Chief Financial Officer) | Option Ex | 3,100 | 4.62 | 14,322 |
| 2020-06-17 | Lackner Mark (SVP, Head of Biology) | Sale | 373 | 19.91 | 7,427 |
| 2020-06-17 | Lackner Mark (SVP, Head of Biology) | Option Ex | 373 | 4.62 | 1,723 |
| 2020-06-16 | Lackner Mark (SVP, Head of Biology) | Sale | 6,750 | 14.93 | 100,764 |
| 2020-06-16 | Lackner Mark (SVP, Head of Biology) | Option Ex | 6,750 | 5.80 | 39,150 |
| 2020-06-04 | Throne Jason (VP, General Counsel) | Sale | 2,205 | 8.66 | 19,086 |
| 2020-06-02 | Lackner Mark (SVP, Head of Biology) | Sale | 845 | 9.46 | 7,995 |
| 2020-04-15 | Hata Yujiro S (President and CEO) | Option Ex | 47,564 | 4.31 | 205,000 |
| 2020-03-30 | Stone Paul A. (Chief Financial Officer) | Option Ex | 5,000 | 4.62 | 23,100 |
| 2019-07-30 | Hata Yujiro S (President and CEO) | Option Ex | 15,000 | 4.31 | 64,649 |
| 2019-07-26 | Stone Paul A. (SVP, General Counsel) | Option Ex | 10,000 | 4.62 | 46,200 |
| 2019-07-26 | Hager Jeffrey (SVP, Chief Technology Officer) | Option Ex | 5,197 | 4.31 | 22,399 |
| 2019-07-10 | Hager Jeffrey (SVP, Chief Technology Officer) | Option Ex | 7,145 | 4.31 | 30,794 |
| 2019-06-19 | Hager Jeffrey (SVP, Chief Technology Officer) | Option Ex | 8,628 | 4.31 | 37,186 |
| 2019-05-28 | Stone Paul A. (SVP, General Counsel) | Buy | 250,000 | 10.00 | 2,500,000 |
| 2019-05-28 | Alexandria Venture Investments, Llc | Buy | 50,000 | 10.00 | 500,000 |
| 2019-05-28 | Canaan Partners X Llc | Buy | 400,000 | 10.00 | 4,000,000 |
| 2019-05-28 | Schwab Andrew J. | Buy | 750,000 | 10.00 | 7,500,000 |
| 2019-05-28 | Diekman John D | Buy | 250,000 | 10.00 | 2,500,000 |
| 2019-05-28 | Shannon Timothy M | Buy | 400,000 | 10.00 | 4,000,000 |
Insider trading activities including stock purchases, stock sales, and option exercises of IDYA listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Ideaya Biosciences, Inc. (symbol IDYA, CIK number 1676725) see the Securities and Exchange Commission (SEC) website.